ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Aurinia Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 12.08%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 92.59 MM
- ROCE(HY) Highest at 17.33%
- INTEREST COVERAGE RATIO(Q) Highest at 3,071.35
2
With ROE of 16.33%, it has a fair valuation with a 3.16 Price to Book Value
- Over the past year, while the stock has generated a return of 81.12%, its profits have risen by 202.3% ; the PEG ratio of the company is 0.1
3
Market Beating performance in long term as well as near term
- Along with generating 81.12% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Aurinia Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aurinia Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aurinia Pharmaceuticals, Inc.
-100.0%
4.33
46.18%
S&P 500
13.02%
0.81
19.85%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
204.27%
EBIT Growth (5y)
23.31%
EBIT to Interest (avg)
-74.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0.55
Tax Ratio
4.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
45.17%
ROCE (avg)
19.90%
ROE (avg)
3.27%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
3.16
EV to EBIT
15.39
EV to EBITDA
11.23
EV to Capital Employed
15.32
EV to Sales
3.27
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
99.51%
ROE (Latest)
16.33%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 92.59 MM
ROCE(HY)
Highest at 17.33%
INTEREST COVERAGE RATIO(Q)
Highest at 3,071.35
RAW MATERIAL COST(Y)
Fallen by -6.5% (YoY
NET SALES(Q)
Highest at USD 70.01 MM
OPERATING PROFIT(Q)
Highest at USD 34.31 MM
PRE-TAX PROFIT(Q)
At USD 22.27 MM has Grown at 49.06%
NET PROFIT(Q)
At USD 21.62 MM has Grown at 51.24%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Aurinia Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 92.59 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Interest Coverage Ratio
Highest at 3,071.35
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
Highest at USD 70.01 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 34.31 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
At USD 22.27 MM has Grown at 49.06%
over average net sales of the previous four periods of USD 14.94 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 21.62 MM has Grown at 51.24%
over average net sales of the previous four periods of USD 14.3 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -6.5% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
